Hematology · 4 h ago
Spanish real-world study reports zanubrutinib outcomes in relapsed marginal zone lymphoma
A retrospective study of 118 patients with relapsed or refractory marginal zone lymphoma in Spain evaluated zanubrutinib effectiveness and safety. At a median follow-up of 14 months, the overall response rate was 76%, while grade 3 or higher adverse events occurred in 14.4%.
- Overall response rate was 76% in 118 patients.
- One-year progression-free survival was 79.4%.
- Grade 3 or higher adverse events occurred in 14.4%.
- Bleeding events were more frequent with anticoagulant therapy.
Researchers retrospectively assessed 118 patients in Spain with relapsed or refractory marginal zone lymphoma (MZL) who received zanubrutinib after at least one prior anti-CD20–based regimen. Median age was 75 years; patients had received a median of 1.5 previous treatment lines. More than a quarter would not have met the eligibility criteria for the phase 2 MAGNOLIA trial, and 68% had cardiovascular comorbidities.
The overall response rate was 76%, including a complete response rate of 22.2%. With median follow-up of 14 months, estimated 1-year progression-free survival was 79.4% and overall survival was 86.8%. Adverse events were reported in 34.1% of patients, including grade 3 or higher events in 14.4%. Adverse events were more frequent in patients who would have been ineligible for MAGNOLIA; bleeding events were more frequent among those receiving anticoagulants.
These retrospective findings describe outcomes in routine care, including patients with characteristics not represented in the trial. They do not include a comparator group, and follow-up was relatively short. The observed bleeding association may be relevant when assessing patients on anticoagulants, but the study does not establish treatment changes or comparative safety.
In practice
For clinicians treating relapsed or refractory MZL, this Spanish retrospective cohort reports responses and short-term outcomes with zanubrutinib in routine practice, including patients who would not have qualified for the MAGNOLIA trial. The findings add real-world evidence but do not compare zanubrutinib with other treatments or establish that it should be preferred. Bleeding events were more frequent among patients receiving anticoagulants, a safety observation to consider in context; the study does not establish a specific management approach.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Blood Advances: Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.